Immune-mediated cochleovestibular disorders continue to present a management challenge to the otolaryngologist. The traditional treatment of these disorders, corticosteroids and/or cyclophosphamide (Cytoxan), has been associated with serious and occasionally life-threatening complications. In this study we report our experience in treating 25 patients with immune-mediated cochleovestibular disorders with methotrexate, a less toxic immunosuppressive agent that has been used extensively in patients with rheumatoid arthritis. Mean duration of treatment was 12.9 months, and adverse reactions were acceptable and reversible. Hearing improved in 69.6% of patients, and vestibular symptoms subsided or improved in 80% of patients. The results of this study suggest that methotrexate treatment is effective in a substantial number of patients with immune-mediated cochleovestibular disorders and has acceptable adverse reactions. A prospective, randomized study is needed to compare the efficacy of methotrexate with that of other immunosuppressive agents.
Get full access to this article
View all access options for this article.
References
1.
McCabeBEAutoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol1979; 88: 585–9.
2.
HughesGBMoscickiRBarnaBPLaboratory diagnosis of immune inner ear disease. Am J Otol1994; 15: 198–202.
3.
HarrisJPSharpPAInner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope1990; 100: 516–24.
4.
MoscickiRASamMartin JEQuinteroCHSerum antibody to inner ear proteins in patients with progressive hearing loss. JAMA1994; 272: 611–6.
HarrisJPDarmstadtGLSensorineural hearing loss: medical therapy. In: Current therapy in otolaryngology-head and neck surgery. Vol. 4. Philadelphia: BC Decker, Inc., 1990: 50–6.
7.
LuetjeCMTheoretical and practical implications for plasmapheresis in autoimmune inner ear disease. Laryngoscope1989; 99: 1137–46.
8.
HughesGBBarnaBPKinneySECalabreseLHKooANalepaNJImmune inner ear disease: 1990 report. Trans Am Otol Soc1990; 78: 86–91.
9.
FauciASWolffSMWegener's granulomatosis studies in eighteen patients and a review of the literature. Medicine1973; 52: 535–61.
10.
FauciASHaynesBFKatzP.NIH conference: the spectrum of vasculitis: clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med1978; 89: 660–76.
11.
HarrisJPAutoimmune diseases affecting the inner ear. Adv Otolaryngol Head Neck Surg1993; 7: 59–76.
12.
SismanisAThompsonTWillisHEMethotrexate therapy for autoimmune hearing loss: a preliminary report. Laryngoscope1994; 104: 932–4.
13.
Physicians' desk reference49th ed.Montvale, N.J.: Medical Economics Data, 1995: 1165–9.
14.
WeinblattMEMethotrexate for chronic diseases in adults. N Engl J Med1995; 332: 330–1.
15.
FeaganBFRochonJFedorakRNMethotrexate for the treatment of Crohn's disease. N Engl J Med1995; 332: 292–7.
16.
WeinblattMECoblynJSFoxDAEfficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med1985; 312: 818–22.
17.
GianniniEHBrewerEJKuzminaNMethotrexate in resistant juvenile rheumatoid arthritis—results of the U.S.A.-U.S.S.R. Double-blind, placebo-controlled trial. N Engl J Med1992; 326: 1043–9.
18.
MullarkeyMFBlumensteinBAAndradeWPBaileyGAOlasonIWetzelCEMethotrexate in the treatment of corticosteroid-dependent asthma: a double-blind crossover study. N Engl J Med1988; 318: 603–7.
19.
WilkensRTResolve: methotrexate is the drug of choice after NSAIDS in rheumatoid arthritis. Semin Arthritis Rheum1990; 20: 76–80.
20.
WeinblattMEWeissmanBNHoldsworthDELong-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum1992; 35: 129–37.
21.
KremerJMPhelpsCTLong-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum1992; 35: 138–45.
22.
WilliamsHJWillkensRFSamuelsonCOJr.Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum1985; 28: 721–30.
23.
MorganSLBaggotJEVaughnWHThe effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum1990; 33: 9–18.
